Ines Levade
Overview
Explore the profile of Ines Levade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henaut M, Carbonneau J, Levade I, Boivin G
J Infect Dis
. 2024 Nov;
PMID: 39520393
The fitness of SARS-CoV-2 Omicron subvariants was determined in human epithelial and continuous cells of the respiratory and gastrointestinal tracts. Competition experiments over 4 days were performed followed by quantification...
2.
Benlarbi M, Ding S, Belanger E, Tauzin A, Poujol R, Medjahed H, et al.
mBio
. 2024 Jul;
15(8):e0090724.
PMID: 38953636
The continued evolution of severe acute respiratory syndrome 2 (SARS-CoV-2) requires persistent monitoring of its subvariants. Omicron subvariants are responsible for the vast majority of SARS-CoV-2 infections worldwide, with XBB...
3.
Fournelle D, Mostefai F, Brunet-Ratnasingham E, Poujol R, Grenier J, Galvez J, et al.
Viruses
. 2024 Mar;
16(3).
PMID: 38543708
Throughout the SARS-CoV-2 pandemic, several variants of concern (VOCs) have been identified, many of which share recurrent mutations in the spike glycoprotein's receptor-binding domain (RBD). This region coincides with known...
4.
Skowronski D, Zhan Y, Kaweski S, Sabaiduc S, Khalid A, Olsha R, et al.
Euro Surveill
. 2024 Feb;
29(7).
PMID: 38362622
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than...
5.
Tauzin A, Beaudoin-Bussieres G, Benlarbi M, Nayrac M, Bo Y, Gendron-Lepage G, et al.
Viruses
. 2023 Sep;
15(9).
PMID: 37766332
While an important part of the world's population is vaccinated against SARS-CoV-2, new variants continue to emerge. We observe that even after a fifth dose of the mRNA bivalent vaccine,...
6.
Dzieciolowska S, Charest H, Roy T, Fafard J, Carazo S, Levade I, et al.
Clin Infect Dis
. 2023 Sep;
78(3):613-624.
PMID: 37675577
Background: There is a need to understand the duration of infectivity of primary and recurrent coronavirus disease 2019 (COVID-19) and identify predictors of loss of infectivity. Methods: Prospective observational cohort...
7.
Beaudoin-Bussieres G, Tauzin A, Dionne K, Gendron-Lepage G, Medjahed H, Perreault J, et al.
Viruses
. 2023 Jun;
15(6).
PMID: 37376574
Since the beginning of the SARS-CoV-2 pandemic, several variants of concern (VOCs), such as the Alpha, Beta, Gamma, Delta and Omicron variants, have arisen and spread worldwide. Today, the predominant...
8.
Henaut M, Carbonneau J, Rheaume C, Levade I, Boivin G
J Clin Virol
. 2023 Jun;
165:105517.
PMID: 37321149
Objective: To develop a new method for reliable and rapid determination of the fitness of SARS-CoV-2 variants of concern. Methods: Competition experiments between two SARS-CoV-2 variants were performed in cells...
9.
Saber M, Donner J, Levade I, Acosta N, Parkins M, Boyle B, et al.
Microb Genom
. 2023 Apr;
9(4).
PMID: 37052589
The severity and progression of lung disease are highly variable across individuals with cystic fibrosis (CF) and are imperfectly predicted by mutations in the human gene CFTR, lung microbiome variation...
10.
Tauzin A, Benlarbi M, Medjahed H, Gregoire Y, Perreault J, Gendron-Lepage G, et al.
Vaccines (Basel)
. 2023 Feb;
11(2).
PMID: 36851122
The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many countries. Because of the many mutations present in its Spike glycoprotein, this variant is resistant to humoral...